ClinicalTrials.gg
Enrolling by invitationNCT04049084Updated Dec 18, 2025

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

An observational study in Adenosine Deaminase Deficiency and Severe Combined Immunodeficiency (SCID), sponsored by University of California, Los Angeles. Enrolling by invitation at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by University of California, Los Angeles · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
70
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States — 2 open to participants now, 4 under way, none of them phase 3. Severe combined immunodeficiency due to adenosine deaminase deficiency · United States.

Started
2019
with 2 others
Observational
7 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
5 of 16
University of California, Los Angeles

Among the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States, this one is one of 3 that started in 2019, is one of 7 observational ones, and was the 14th registered.

Severe combined immunodeficiency due to adenosine deaminase deficiency

29 studies on the registry are indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency; 4 are open to participants now.

Browse Severe combined immunodeficiency due to adenosine deaminase deficiency studies →

Open to participants now

2 of the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States, or all of them as a file.
02

Study summary

This observational long-term follow-up study is designed to collect safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA LV encoding for human adenosine deaminase (ADA) gene (EFS-ADA LV), as part of the OTL-101 clinical development program. No investigational medicinal product will be administered to these patients as part of the OTL-101-6 study.

Read the detailed description

The overall aim of this study is to record and evaluate long-term safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA vector, as part of the UCL/A- ADA clinical development program. This will fulfil the requirements for the monitoring of delayed adverse events set by regulatory agencies for subjects treated with gene therapies.

The study will have the following specific objectives:

  • To characterize the long-term safety of the gene therapy treatment;
  • To characterize the long-term clinical efficacy of the gene therapy treatment. Patients who were treated as part of the UCL/A-ADA clinical development program but did not complete the expected follow- up period (e.g. as a consequence of early withdrawal due to safety events) will be included in the LTFU study, subject to their consent and compliance with inclusion and exclusion criteria.

For any patients who completed their expected follow-up period before this study became available, outcome data will be retrospectively collected for the intervening period. From the first LTFU assessment onwards, prospective data will be gathered from the annual standard of care evaluations the patients will receive from the PI or their local healthcare professionals (HCPs).

Each patient, or their legal guardian, will be required to provide informed consent, which will define the objectives of this study, the expected duration of the patient's participation, as well as the data to be collected and the schedule of collection. It is anticipated that data will be collected annually to coincide with standard of care visits.

The study outcomes will be:

  • Overall survival (OS) at 15 years of follow-up post treatment with gene therapy;
  • Event-free survival (EvFS) at 15 years of follow-up post treatment with gene therapy. An "event" will be defined as enzyme replacement therapy (ERT) reinstitution, need for a rescue allogeneic hematopoietic stem cell transplant (HSCT) or further gene therapy treatment;
  • Use of immunoglobulin replacement therapy (IgRT);
  • Adverse events (AEs), serious adverse events (SAEs) and safety concerns
  • Other physical and laboratory parameters
03

Conditions studied

  • Adenosine Deaminase Deficiency
  • Severe Combined Immunodeficiency (SCID)

Keywords

  • OTL-101
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This observational LTFU study is open for enrollment to ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA lentiviral vector as part of the OTL-101 clinical development program. Patients treated in clinical trials as part of IND #15440, study OTL-101-5 (EudraCT No 2017-001275-23) or study 10-MI-29 (EudraCT No 2010-024253-36), as well as in Expanded Access or Compassionate Use Programs, will be eligible for enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient is eligible for enrollment in the study if all of the following criteria are met:

  1. the patient has been treated with an autologous ex vivo gene therapy product based on the EFS-ADA LV, as part of the OTL-101 clinical development program;
  2. the patient displays persistent detectable gene marking, as determined by the Investigator;
  3. the patient or, if applicable, the patient's parent(s)/legal guardian(s), are able and willing to provide .

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria for participation in this observational LTFU study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
70 participants (estimated)
Target follow-up
13 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • Biologicalautologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)

    ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Establishing efficacy through overall survival

    Time frame: 15 years post-treatment

  2. Event-Free Survival

    Establishing efficacy through event-free survival

    Time frame: 15 years post-treatment

  3. Incidence of Adverse Events

    Long-Term Safety incidence of AEs and SAEs

    Time frame: 15 years post-treatment

07

Study locations

2 sites
  • Mattel Children's Hospital UCLA/Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • UCL Great Ormond Street Institute of Child Health
    London, WC1N 1EH, United Kingdom
08

References and documents

Publications

  • Booth C, Masiuk K, Vazouras K, Fernandes A, Xu-Bayford J, Campo Fernandez B, Roy S, Curio-Penny B, Arnold J, Terrazas D, Reid J, Gilmour KC, Adams S, Alvarez Mediavilla E, Mhaldien L, O'Toole G, Ahmed R, Garabedian E, Malech H, De Ravin SS, Moore TB, De Oliveira S, Pellin D, Lin TY, Dang TT, Cornetta K, Hershfield MS, Hara H, Thrasher AJ, Gaspar HB, Kohn DB. Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. N Engl J Med. 2025 Oct 16;393(15):1486-1497. doi: 10.1056/NEJMoa2502754. PubMed 41092330 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2019 (actual). Primary completion is estimated for Aug 2040, 251 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2019
First posted
Aug 7, 2019
StartActual
Sep 26, 2019
Primary completionEst.
Aug 2040
CompletionEst.
Aug 2040
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04049084
Collaborators
Great Ormond Street Hospital for Children NHS Foundation Trust
Responsible party
Donald B. Kohn, M.D. (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Aug 7, 2019
Start date
Sep 26, 2019
Primary completion
Aug 2040 (estimated)
Completion
Aug 2040 (estimated)
Last update
Dec 18, 2025

Study contacts

Donald B. Kohn, M.D.
study director · University of Califorina, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion